Research progress in treatment strategies and prognostic factors for stage pT2-3N0M0 thoracic esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20240528-00006

Abstract

Abstract:

Although patients with stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma are staged earlier， their postoperative local recurrence and distant metastasis rates are higher， resulting in a low five-year survival rate of such patients. The current neoadjuvant treatment for such patients is still in the research stage， and whether to give adjuvant radiotherapy and chemotherapy after surgery is still controversial. In addition， the prognostic factors of patients with pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma have not yet been clarified， and the causes of recurrence and metastasis are not yet clear. Therefore， it is of great significance to clarify treatment strategies and explore the impact of prognostic factors on improving the survival rate of such patients， which is expected to provide new directions for improving the prognosis and survival rate of patients with pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma.

Key words: Esophageal squamous cell carcinoma, Antineoplastic protocols, Prognosis

Yu Yang, Tang Shimin, Yang Lu, Li Na. Research progress in treatment strategies and prognostic factors for stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(1): 43-47.

References 34

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI:10.3760/cma.j.cn112152-20240119-00035.
[3]	Deng W, Yang J, Ni W, et al. Postoperative radiotherapy in pathological T_2-3N₀M₀ thoracic esophageal squamous cell carcinoma: interim report of a prospective, phase Ⅲ, randomized controlled study[J]. Oncologist, 2020, 25(4): e701-e708. DOI: 10.1634/theoncologist.2019-0276.
[4]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2023[M]. 北京: 人民卫生出版社, 2023.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2023年版)[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20. DOI: 10.3760/cma.j.cn371439-20231221-00001.
[6]	National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric Junction Cancers, Version 3. 2024[EB/OL]. (2024-04-26) [2024-05-21]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[7]	de Groot EM, Goense L, Kingma BF, et al. Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update[J]. Dis Esophagus, 2023, 36(7): doac099. DOI: 10.1093/dote/doac099.
[8]	中华人民共和国国家卫生健康委员会医政医管局. 食管癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(10): 1247-1268. DOI: 10.3760/cma.j.cn115610-20220726-00433.
[9]	Yoshida N, Yamamoto H, Baba H, et al. Can minimally invasive esophagectomy replace open esophagectomy for esophageal cancer? Latest analysis of 24,233 esophagectomies from the Japanese National Clinical Database[J]. Ann Surg, 2020, 272(1): 118-124. DOI: 10.1097/SLA.0000000000003222. pmid: 30720501
[10]	Wang BY, Lin CH, Wu SC, et al. Survival comparison between open and thoracoscopic upfront esophagectomy in patients with esophageal squamous cell carcinoma[J]. Ann Surg, 2023, 277(1): e53-e60. DOI: 10.1097/SLA.0000000000004968.
[11]	中国抗癌协会食管癌专业委员会. 机器人辅助食管切除术中国临床专家共识(2023版)[J]. 中华胸部外科电子杂志, 2024, 11(1): 1-15. DOI: 10.3877/cma.j.issn.2095-8773.2024.01.01.
[12]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[13]	Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial[J]. Ann Oncol, 2023, 34(2): 163-172. DOI: 10.1016/j.annonc.2022.10.508.
[14]	Wakita A, Motoyama S, Sato Y, et al. Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T₃ thoracic esophageal cancer[J]. Ann Gastroenterol Surg, 2023, 7(6): 904-912. DOI: 10.1002/ags3.12706.
[15]	Song C, Zhu S, Xu J, et al. Patterns of failure and long-term outcome of postoperative radiotherapy on the survival of patients with pathological T₃N₀M₀ esophageal cancer[J]. Front Surg, 2022, 9: 959568. DOI: 10.3389/fsurg.2022.959568.
[16]	Yang H, Li X, Yang W. Advances in targeted therapy and immunotherapy for esophageal cancer[J]. Chin Med J (Engl), 2023, 136(16): 1910-1922. DOI: 10.1097/CM9.0000000000002768.
[17]	Ge F, Huo Z, Cai X, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(11): e2239778. DOI: 10.1001/jamanetworkopen.2022.39778.
[18]	Asakura T, Hashimoto T, Ando T, et al. Degree of differentiation of esophageal squamous cell carcinoma and micrometastasis to lymph nodes[J]. Juntendo Iji Zasshi, 2022, 68(4): 363-368. DOI: 10.14789/jmj.JMJ21-0041-OA. pmid: 39021430
[19]	Feng W, Qi Z, Qiu R, et al. Risk factors for tumor recurrence in patients with pT₃N₀M₀ thoracic esophageal squamous cell carcinoma after esophagectomy[J]. J Int Med Res, 2020, 48(12): 300060520 977403. DOI: 10.1177/0300060520977403.
[20]	Kim HE, Park SY, Kim H, et al. Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma[J]. Thorac Cancer, 2021, 12(10): 1605-1612. DOI: 10.1111/1759-7714.13960. pmid: 33811752
[21]	Guo YN, Tian DP, Gong QY, et al. Perineural invasion is a better prognostic indicator than lymphovascular invasion and a potential adjuvant therapy indicator for pN₀M₀ esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(11): 4371-4381. DOI: 10.1245/s10434-020-08667-4.
[22]	Haneda R, Kikuchi H, Nagakura Y, et al. Development and validation of the optimal circumferential resection margin in pathological T₃ esophageal cancer: a multicenter retrospective study[J]. Ann Surg Oncol, 2022, 29: 4452-4461. DOI: 10.1245/s10434-022-11491-7.
[23]	Okada NY, Fujii S, Fujita TK, et al. The prognostic significance of the positive circumferential resection margin in pathologic T₃ squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy[J]. Surgery, 2016, 159(2): 441-450. DOI: 10.1016/j.surg.2015.06.044.
[24]	王崇礼, 曹富民. 食管鳞癌环周切缘的临床意义分析[J]. 中华胸心血管外科杂志, 2022, 38(1): 5-12. DOI: 10.3760/cma.j.cn112434-20201218-00541.
[25]	Kang M, Wang Y, Yang M, et al. Prognostic nomogram and risk factors for predicting survival in patients with pT₂N₀M₀ esophageal squamous carcinoma[J]. Sci Rep, 2023, 13(1): 4931. DOI: 10.1038/s41598-023-32171-w. pmid: 36967413
[26]	Li J, Mei X, Sun D, et al. A nutrition and inflammation-related nomogram to predict overall survival in surgically resected esophageal squamous cell carcinoma (ESCC) patients[J]. Nutr Cancer, 2022, 74(5): 1625-1635. DOI: 10.1080/01635581.2021.1957131.
[27]	中国抗癌协会肿瘤放射治疗专业委员会, 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会. 食管癌放疗联合免疫治疗专家共识(2023年版)[J]. 中华放射医学与防护杂志, 2023, 43(8): 575-587. DOI: 10.3760/cma.j.cn112271-20230626-00207.
[28]	Kato K, Ito Y, Daiko H, et al. A randomized controlled phase Ⅲ trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study[J]. J Clin Oncol, 2022, 40(4_suppl): 238-238. DOI: 10.1200/JCO.2022.40.4_suppl.238.
[29]	Wang Q, Peng L, Li T, et al. Postoperative chemotherapy for thoracic pathological T₃N₀M₀ esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(5): 1488-1495. DOI: 10.1245/s10434-019-08112-1.
[30]	Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase Ⅱ trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(3): e004291. DOI: 10.1136/jitc-2021-004291.
[31]	Kang K, Wu J, Mao Y, et al. Role of SLC44A3-AS1 enhancer RNA in esophageal cancer prognosis[J]. J Coll Physicians Surg Pak, 2023, 33(9): 964-971. DOI: 10.29271/jcpsp.2023.09.964. pmid: 37691355
[32]	Zhou L, Gan L, Liu Z. Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma[J]. Medicine (Baltimore), 2023, 102(34): e34677. DOI: 10.1097/MD.0000000000034677.
[33]	Song WP, Wang SY, Zhou SC, et al. Prognostic and clinicopathological value of twist expression in esophageal cancer: a meta-analysis[J]. World J Gastrointest Oncol, 2022, 14(9): 1874-1886. DOI: 10.4251/wjgo.v14.i9.1874.
[34]	向光宇, 李家贺, 季刚, 等. 单细胞RNA测序技术在食管鳞状细胞癌辅助诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(12): 745-748. DOI: 10.3760/cma.j.cn371439-20220816-00146.

Research progress in treatment strategies and prognostic factors for stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 34

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ye Yongying, Zou Yan, Chen Tianming, Wu Weili. Research progress of clock gene Period family in head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2025, 52(2): 113-118.
[2]	Chen Danlei, Deng Junjun, Li Miao. Progress of clinical application of circulating tumor cells in lung cancer [J]. Journal of International Oncology, 2025, 52(2): 119-123.
[3]	Ma Peihan, Zhang Lingmin, Li Qian, Lu Ning, Wen Hua, Zhang Mingxin. Effects of ALKBH5 on the malignant biological behavior of esophageal squamous cell carcinoma and the related mechanism [J]. Journal of International Oncology, 2025, 52(2): 79-88.
[4]	Ji Haitao, Wang Yanfeng, Liu Yongcheng, Hao Nan. Expression and clinical significance of DHCR7 in gastric cancer based on bioinformatics analysis [J]. Journal of International Oncology, 2025, 52(2): 94-100.
[5]	Wu Xiaowei, Hu Ge, Chen Li, Qian Xiaotao, Cui Xiangli, Zhu Fengqin. Predictive value of pre-radiotherapy maximum tumor diameter and peripheral blood NLR for esophageal fistula in esophageal squamous carcinoma patients [J]. Journal of International Oncology, 2025, 52(1): 38-42.
[6]	Yuan Shengfang, Ren Jie, Lin Weijia, Ji Zexuan, Zhang Changhong, Wang Bu. Prognostic value of EGFR co-mutation status in patients with advanced lung adenocarcinoma [J]. Journal of International Oncology, 2024, 51(9): 556-562.
[7]	Ni Guoying, Huang Qian, Liang Hongxiang, Yang Zhiyong, Ding Yingli. Analysis of changes in serum miR-499 and miR-362 levels and their relationship with prognosis in advanced NSCLC patients [J]. Journal of International Oncology, 2024, 51(8): 487-492.
[8]	Meng Kexin, Lu Haijun. Oral microbiota：a biomarker for the diagnosis and prognosis of oral squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(8): 515-519.
[9]	Han Yi, Zhang Tongmei, Qi Fei, Zhang Yong. Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma [J]. Journal of International Oncology, 2024, 51(7): 468-473.
[10]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[11]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[15]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.